Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra P...
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
...
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 126
- Registration Number
- NCT00049569
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Riverside Haematology Group
- Target Recruit Count
- 400
- Registration Number
- NCT00003602
- Locations
- 🇬🇧
Newcastle Upon Tyne Hospitals NHS Trust, Newcastle-Upon-Tyne, England, United Kingdom
Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 120
- Registration Number
- NCT00040690
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00002598
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-06-06
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004231
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Leukemia Research Fund
- Target Recruit Count
- 2000
- Registration Number
- NCT00005823
- Locations
- 🇬🇧
University Hospital of Wales, Cardiff, Wales, United Kingdom
🇬🇧University College Hospital, London, England, United Kingdom
🇬🇧Queen Elizabeth Hospital at University of Birmingham, Birmingham, England, United Kingdom
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- III. Medizinische Klinik Mannheim
- Target Recruit Count
- 1000
- Registration Number
- NCT00025402
- Locations
- 🇩🇪
Tumorzentrum Berlin-Moabit, Berlin, Germany
🇩🇪Wenckebach - Krankenhaus, Berlin, Germany
🇩🇪Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 32
- Registration Number
- NCT00039117
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 1800
- Registration Number
- NCT00003437
- Locations
- 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 276
- Registration Number
- NCT00005603
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.